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Abstract
We examined 13 single nucleotide polymorphisms (SNPs) spanning the coding region of the μ-
opioid receptor gene (OPRM1), among 382 European Americans (EAs) affected with substance
dependence [alcohol dependence (AD) and/or drug dependence (DD)] and 338 EA healthy
controls. These SNPs delineated two haplotype blocks. Genotype distributions for all SNPs were
in Hardy–Weinberg equilibrium (HWE) in controls, but in cases, four SNPs in Block I and three
SNPs in Block II showed deviation from HWE. Significant differences were found between cases
and controls in allele and/or genotype frequencies for six SNPs in Block I and two SNPs in Block
II. Association of SNP4 in Block I with DD (allele: P = 0.004), SNP5 in Block I with AD and DD
(allele: P ≤ 0.005 for both) and two SNPs in Block II with AD (SNP11 genotype: P = 0.002;
SNP12 genotype: P = 0.001) were significant after correction for multiple testing. Frequency
distributions of haplotypes (constructed by five tag SNPs) differed significantly for cases and
controls (P < 0.001 for both AD and DD). Logistic regression analyses confirmed the association
between OPRM1 variants and substance dependence, when sex and age of subjects and alleles,
genotypes, haplotypes or diplotypes of five tag SNPs were considered. Population structure
analyses excluded population stratification artifact. Additional supporting evidence for association
between OPRM1 and AD was obtained in a smaller Russian sample (247 cases and 100 controls).
These findings suggest that OPRM1 intronic variants play a role in susceptibility to AD and DD in
populations of European ancestry.
Introduction
The μ-opioid receptor (MOR; encoded by genetic locus OPRM1) is widely distributed in the
brain, and is highly expressed in the thalamus, caudate putamen and globus pallidus (1).
MOR has a high affinity for β-endorphin and enkephalin but a low affinity for dynorphin
(which preferentially binds to the κ-opioid receptor), and it also binds exogenous opioid
drugs (e.g. morphine, heroin and methadone) with a high affinity. MORs are thought to be
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responsible for most opioidergic actions such as euphoria, analgesia and opiate drug
withdrawal (2).
Disruption of the MOR gene (Oprm) in mice abolishes morphine-induced analgesia, place-
preference activity and physical-dependence, even in the presence of intact δ- and κ-opioid
receptors (DOR and KOR) (3,4). In addition, non-opioid substances, such as cocaine and
alcohol, may exert some of their effects directly or indirectly by interacting with the MOR.
Cocaine and ethanol each affect the function of both mesolimbic dopamine and endogenous
opioid systems. They stimulate dopamine release in rat nucleus accumbens (NAc), the
terminal region in the mesolimbic dopamine pathway, which is thought to be the critical
brain region mediating the reinforcing effects of drugs of abuse (5). They also increase brain
levels of β-endorphin, which triggers neuronal MOR to generate a reward sensation (6,7).
Ethanol alone or in combination with cocaine raises MOR levels in rat brain (8). As these
two systems are intimately related, altered levels or function of the MOR may in turn
modulate NAc dopaminergic activity. For example, infusion of MOR agonists into the
ventral tegmental area (VTA), in which the MOR is expressed, increases dopamine release
into the NAc, whereas infusion of MOR antagonists decreases dopamine release (9).
Furthermore, the murine MOR gene (Oprm) has been mapped close to a major quantitative
trait locus (QTL) controlling morphine preference in inbred mice (10,11). Naltrexone, one of
only three approved pharmacotherapies for AD, is thought to exert its actions primarily by
blocking the MOR (12,13).
These observations suggest that the MOR, and therefore, potentially the OPRM1 gene, are
of major importance in drug dependence and alcoholism. At least 20 studies have attempted
to identify associations between OPRM1 variants and vulnerability to substance dependence.
Of particular interest is a single nucleotide polymorphism (SNP) located at position 118 in
exon 1 (118A/G), causing an amino acid substitution (Asn40 to Asp40) that removes a
highly conserved N-glycosylation site in the extracellular domain of the protein (14,15). The
MOR encoded by variant Asp40 has been reported to bind the endogenous opioid peptide β-
endorphin with 3-fold greater affinity than receptors coded by variant Asn40 (15). However,
three follow-up studies either failed to confirm this finding (16,17) or provided evidence for
reduced receptor expression due to variant Asp40 (18). Because of its potential functional
significance, SNP Asn40Asp has been intensively studied for its potential association with
substance dependence phenotypes, but the results from these studies are inconclusive (19).
Among the published reports, four studies demonstrated that the Asp40 allele was more
prevalent among heroin or AD individuals (20–22) or was associated with a heavier drinking
pattern (23), consistent with the interpretation that the Asp40 allele may cause enhanced
sensitivity to the effects of alcohol or drugs of abuse. Three other studies reported opposite
results, i.e. a lower frequency of the Asp40 allele in the substance-dependent group (24–26).
The remaining 13 studies failed to show an association with this variant (14,15,23,27–36).
The second most commonly studied polymorphism in the OPRM1 gene is the 17C/T SNP,
which is located at position 17 of exon 1 and causes an amino acid change from Ala6(C) to
Val6(T). Although one study showed a trend towards an increased frequency of the Val6
allele in AD subjects (37), all other studies have shown no association (14,26,27,31,32,34).
Several rare polymorphisms within the coding regions, for example, Ser147Cys in exon 2
and Ile292Val in exon 3, have also been studied, but their significance is unknown (14,30).
Two studies used haplotype-based approaches to investigate the impact of variations in
OPRM1 on the risk for substance-dependence. The OPRM1 variants examined in these
studies were located in the putative 5′ regulatory region (−2044C/A, −1793T/A, −1699insT,
−1469T/C and −1320A/G), the 5′ untranslated region (5′ UTR) (−111C/T), and exon 1
(Ala6Val and Asn40Asp). Haplotypes composed of polymorphisms mainly in the putative
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transcription regulatory region were found to be weakly associated with substance
dependence (28,32). Finally, Kranzler et al. (38) observed a modest association of a
polymorphic (CA)n repeat in intron 1 with AD or DD.
Gene variants in the 5′ regulatory region (including the promoter region) can alter the
transcription initiation site or the capacity of transcription factors to bind to the DNA
sequence, and consequently, affect transcription levels. In addition, sequence variation in the
5′ UTR may result in mRNA instability or altered translational efficiency, or even different
protein expression levels in different tissues. Results obtained by Hoehe et al. (28) and Luo
et al. (32) may be due to the fact that the polymorphisms examined are within the 5′ region
of the OPRM1 gene. A more difficult question is how to interpret the contradictory results of
the most-studied SNP, Asn40Asp. As noted earlier, although SNP Asn40Asp is very likely a
functional polymorphism, most previous studies do not support its role as a risk locus for
substance dependence. The conflicting results could be due to any of several possible
explanations, including inadequate statistical power, genetic heterogeneity or admixture
within the population groups studied. Indeed, the frequency of the Asp40 allele varied from
as low as 0.047 in African Americans (AAs) and 0.154 in European Americans (EAs), and
was as high as 0.485 in those of Asian descent (27). Nevertheless, these explanations are
still not sufficient, as some of the previous studies were conducted in large samples and
subjects were from relatively homogeneous population groups. The frequently negative but
occasionally positive findings from SNP Asn40Asp raise another possibility: Asn40Asp,
although a clearly functional variant with relevant physiological effects (39), may be in
linkage disequilibrium (LD) with an additional risk locus that has a greater effect on disease
susceptibility. Such LD could plausibly vary by population, as well. Exonic variants in
OPRM1 have already been vigorously examined. Except for the Asn40Asp and Ala6Val
SNPs in exon 1, other exonic variants are not sufficiently polymorphic to account for a
substantial proportion of disease risk on the population level (14,28). As a consequence, our
attention was drawn to gene variants within introns, which may serve as binding sites for
transcriptional enhancers or inhibitory factors that may be located in introns or other non-
coding regions. Even a SNP variant may greatly change the affinity of these transcriptional
regulatory factors for the intronic DNA sequence and directly alter mRNA levels (40). In
fact, Shi et al. (30) investigated an OPRM1 SNP in intron 2 (IVS2 + 31G→A) in 232 Han
Chinese heroin addicts and found that heterozygous subjects (A/G) reported greater heroin
intake than did GG homozygotes. The mechanism for this finding is unknown.
In addition, intronic sequence can be involved in alternative DNA splicing. To date, nine
human OPRM1 splice variants have been identified (41–43). They contain the same exons 1,
2 and 3 as the original human OPRM1, which normally has four exons. However, they differ
from this sequence and from each other by splicing downstream from exon 3. All splice
variants result in amino acid sequence changes in the C-terminus of the MOR and may
affect the activity (e.g. phosphorylation and internalization) of the receptor.
Most OPRM1 variants have not previously been examined for association with AD or DD,
possibly because attention has been firmly focused on the ‘functional’ exon 1 variant
discussed earlier. We hypothesized that the variants located 3′ to the exon 1 variants might
influence susceptibility to substance dependence. If any such variants were found to be in
LD with SNP Asn40Asp, they could also account, in part, for previously reported findings.
We examined the association of alleles, genotypes, haplotypes and diplotypes of 13 SNPs
covering the coding region of OPRM1 (Fig. 1) with substance dependence [including AD
and DD (cocaine and opioid)] in a large EA case-control sample. Furthermore, 37 ancestry
informative markers (AIMs), which can efficiently distinguish the ancestry of major
American populations (44,45), were genotyped in all EA subjects, and were used to evaluate
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the potential for spurious association resulting from population stratification and admixture
effects. Finally, replication of the findings obtained in the EA sample was sought in a
smaller Russian sample consisting of alcohol-dependent and control subjects.
Results
Hardy–Weinberg equilibrium (HWE) tests and haplotype blocks
HWE tests were performed using the program HWSIM (46) with 10 000 simulations. The
genotype frequency distributions of the 13 OPRM1 SNPs were in HWE in all EA control
subjects, but those of seven SNPs (SNPs 2–5 in intron 1 and SNPs 10–12 in intron 3) were
in Hardy–Weinberg disequilibrium (HWD) (two-tailed P < 0.05) in EAs with AD and/or
DD.
LD analyses of our EA case and control subjects using the program Haploview (47) showed
that the 13 SNPs were located in two separate haplotype blocks (Fig. 2). SNPs 1–7 (SNP1 in
exon 1 and SNP2–7 in intron 1) were in Block I and SNPs 8–13 (SNP8 in intron 2, SNP9–
12 in intron 3 and SNP13 in the downstream region) were in Block II. The LD patterns of
the 13 SNPs in the EA cases were very similar to those of the EA controls.
Association of OPRM1 SNPs and substance dependence
The allele and genotype frequencies of the 13 SNPs in EA cases and controls are listed in
Table 1A and 1B. Comparison of genotype frequency distributions and allele frequencies
revealed significant differences between AD and/or DD cases and normal controls for six
SNPs in Block I (SNPs 2–7 in intron 1) and two SNPs (SNPs 11 and 12 in intron 3) in Block
II. The minor alleles of six SNPs (SNPs 2–7) in Block I occurred significantly more
frequently in AD and/or DD subjects than in normal controls (P < 0.05 in all cases). In
contrast, the minor alleles of two SNPs (SNPs 11 and 12) in Block II were significantly less
frequent in AD and/or DD cases than in normal controls (both P < 0.05). The significance
threshold P-value was set at 0.005 by the program SNPSpD (48) for both AD and DD multi-
locus case-control studies. The association of SNP4 (rs3823010) in intron 1 with DD (allele:
P = 0.004), SNP5 (rs495491) in intron 1 with both AD and DD (allele: P = 0.005 and 0.004,
respectively) and two SNPs in intron 3 with AD [SNP11 (rs609148) genotype: P = 0.002;
SNP12 (rs648893) genotype: P = 0.001] remained significant after correction for multiple
testing. In addition, when the DD cohort was analyzed as separate (and partially
overlapping) cocaine- and opioid-dependent subgroups (CD and OD), the results tended to
be more statistically significant for the OD sample, although its size was small. P-values for
both allele-wise and genotype-wise association analyses are summarized in Figure 3.
To confirm the major findings, two SNPs in each haplotype block, SNP4 (rs3823010) and
SNP5 (rs495491) (in Block I), and SNP11 (rs609148) and SNP12 (rs648893) (in Block II),
were genotyped in the sample of Russian AD and control subjects. Genotype frequency
distributions of the four markers were in HWE in both Russian cases and controls. As in EA
samples, SNP4 and SNP5 were located in the OPRM1 haplotype Block I (D′ = 1.000 for
both Russian cases and controls) and SNP11 and SNP12 were located in the haplotype
Block II (D′ = 1.000 for both Russian cases and controls). As can be seen in Table 1C, the
minor allele (C-allele) of SNP5 (rs495491) was significantly more common in cases than in
controls (χ2 = 5.15, df = 1, P = 0.023), and SNP5 C/C homozygotes were twice as common
in Russian cases (11.6%) as in Russian controls (5.1%) (χ2 = 5.01, df = 2, P = 0.081).
Although no significant results were found for SNPs 4, 11 and 12, as for EA samples, the
minor allele of SNP4 tended to be more frequent in Russian cases (19.6%) than in Russian
controls (16.7%), but the minor allele of SNP11 and SNP12 tended to be less frequent in
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Russian cases (24.9 and 25.4%, respectively) than in Russian controls (27.8 and 29.9%,
respectively).
Selection of five tag SNPs and haplotype association with substance dependence
Because the 13 OPRM1 SNPs studied were located in two haplotype blocks, we used the
Tagger function in the program Haploview to select a comparatively non-redundant set of
SNPs (i.e. tag SNPs) that could predict other SNP markers. Three SNPs in Block I (SNPs 1,
4 and 5) and two SNPs in Block II (SNPs 11 and 12), which capture most of the allelic
diversity of the 13 OPRM1 SNPs, were selected for haplotype analysis.
Estimation of haplotype frequencies and comparison of haplotype frequency distributions
between cases and controls were conducted using the program PHASE (49). As shown in
Table 2, there was a significant difference between EA cases and controls (EA–AD versus
EA–Con: overall P = 5 × 10−5; EA–DD versus EA–Con: overall P = 2.5 × 10−4). In this
population, the haplotype AGTTC, which contains major alleles of SNPs 4 and 5 in Block I
and minor alleles of SNPs 11 and 12 in Block II, was significantly more common in controls
than in cases [AGTTC versus all other haplotypes: χ2 = 4.36, df = 1, P = 0.037 (AD); χ2 =
9.63, df = 1, P = 0.002 (DD)]. In contrast, the counterpart haplotype AACCT, containing
minor alleles of SNPs 4 and 5 in Block I and major alleles of SNPs 11 and 12 in Block II,
was significantly more common in EA cases than in EA controls [AACCT versus all other
haplotypes: χ2 = 5.54, df = 1, P = 0.019 (AD); χ2 = 6.93, df = 1, P = 0.008 (DD)] (note that
the common ‘A’ allele at SNP1 was present in both). When the frequency distributions of
haplotypes constructed from SNPs 4 and 5 in Block I and SNPs 11 and 12 in Block II were
compared for Russian AD cases and controls, no significant difference was found (overall P
= 0.153). However, haplotype GTTC, comprising the major alleles of SNPs 4 and 5 in Block
I and the minor alleles of SNPs 11 and 12 in Block II, was more frequent in Russian controls
(27.4%) than in Russian cases (22.5%). Although, this did not reach significance, the finding
in the Russian samples was in the same direction as that in the EA samples. Similarly, there
was a non-significant trend for the counterpart haplotype ACCT (consisting of the minor
alleles of SNPs 4 and 5 in Block I and the major alleles of SNPs 11 and 12 in Block II) to be
more frequent in Russian cases (17.2%) than in Russian controls (14.6%). However, the
difference in frequency of the two haplotypes, GTTC and ACCT, in Russian cases and
controls did not approach significance (haplotype GTTC: χ2 = 1.71, df = 1, P = 0.191;
haplotype GTTC: χ2 = 0.57, df = 1, P = 0.448).
Population stratification excluded
Population structure analyses revealed that all 720 of the self-reported EA subjects (382
cases and 338 controls) were ‘genetic’ EAs, with the average European ancestry being 0.987
± 0.033 (mean ± SD). In these 720 ‘genetic’ EA subjects, the total estimated weight of
African ancestry proportion was 9.661, i.e. the degree of admixture of the ‘genetic’ EAs in
this study was 1.3% (9.661/734). The proportion of European ancestry for subjects exceeded
0.9 for all but 10 EA cases and five EA controls, for whom this proportion varied from 0.5
to 0.9. The low degree of admixture in the EA samples indicated that population structure
did not exert a substantial effect on this EA case-control study. To investigate further
whether a difference in European ancestry proportions between the EA cases and controls
could compromise the association result, the potential of stratification for our sample was
evaluated using the program STRAT (and the ancestry proportions from STRUCTURE),
which implements the method described in Pritchard and Rosenberg (50). No significant
difference in European ancestry proportions was found between EA cases and controls (Σχ2
= 278.378, df = 83, P = ns). Therefore, the positive association result obtained in the EA
case-control analysis was unlikely to be due to population admixture. In addition, as
Zhang et al. Page 5
Hum Mol Genet. Author manuscript; available in PMC 2011 September 2.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
expected, based on the known non-African origin of the Russian population, the frequency
of the FY(−) polymorphism was very low in the Russian samples (frequency <0.0025) (51).
Regression analysis: OPRM1 alleles, genotypes, haplotypes and diplotypes affect risk for
substance dependence
As shown in the online Supplement 1, significant differences in sex and age between EA
cases and controls were observed (P-values <0.001 for both variables). Thus, we tested
whether the association between OPRM1 variants (five tag SNPs, i.e. SNPs 1, 4, 5, 11 and
12) and substance dependence was attributable to differences in age- and/or sex-related
penetrance. Backward stepwise logistic regression analysis showed that SNP5 (rs495491) in
Block I and SNP11 (rs609148) in Block II were associated with AD and DD, when the sex
and age information of subjects was taken into consideration. Specifically, the minor allele
(C-allele) of SNP5 was a risk factor for both AD [β = 0.77, P = 0.045, odds ratio (OR) =
2.17] and DD (β = 0.69, P = 0.048, OR = 2.00) and it exerted its effect on susceptibility to
AD and DD via a recessive mode of action. In other words, subjects homozygous for the
SNP5 C-allele had 2.17 and 2.00 times of risk to be affected with AD and DD, respectively,
compared with the SNP5 T-allele. In contrast, the minor allele (T-allele) of SNP11 was a
protective allele for both AD (β = −0.50, P = 0.032, OR = 0.60) and DD (β = −0.56, P =
0.019, OR = 0.57) consistent with a dominant mode of action. Thus, the presence of the
SNP11 T-allele reduced the risk of AD and DD by 0.40 and 0.43, respectively. Although the
SNP11 T-allele also showed a protective role for DD in an additive model of inheritance (β
= −0.81, P = 0.040, OR = 0.44, as demonstrated by the results of the allele regression
analysis or Model 1), the results were less significant than those obtained with a dominant
mode of action for DD (P = 0.019). Thus, the SNP11 T-allele is more likely to play a
protective role for DD via a dominant mode of action.
Haplotype and diplotype trend regression (DTR) analysis also showed an association
between OPRM1 variants and substance dependence. The aforementioned haplotype
AGTTC, which contained the major alleles of SNPs 4 and 5 and the minor alleles of SNPs
11 and 12 and which was significantly more frequent in EA controls than in EA cases, was
protective for AD (β = −1.01, P = 0.011, OR = 0.37) and DD (β = −1.37, P = 0.002, OR =
0.26). Furthermore, two diplotypes containing the haplotype AGTTC showed a protective
effect for both AD (AGTCT/AGTTC: β = −0.68, P = 0.046, OR = 0.51; AGTTC/AGCCT: β
= − 1.51, P = 0.009, OR = 0.22) and DD (AGTCT/AGTTC: β = −0.74, P = 0.030, OR =
0.48; AGTTC/AGCCT: β = −1.63, P = 0.011, OR = 0.20). When we performed forward
logistic regression analysis, the results were consistent with the results obtained using the
backward stepwise method.
Discussion
The aim of this study was to explore whether genetic variation at the OPRM1 locus is a risk
factor for AD and/or DD. While there have been numerous previous studies of specific
variants (generally relatively uninformative ones, mapping either 5′ to the locus or in exon
1), this is, to our knowledge, the first attempt to evaluate a series of markers spanning the
coding sequence of the locus; also, no previous study has, to our knowledge, considered
informative markers that map 3′ to exon 1. We previously tested the association of the two
most commonly studied OPRM variants, Ala6Val and Asn40Asp (located in exon 1), with
substance dependence [(27) sample expanded in the present study]. However, as for most
previous studies, allelic association analyses were not significant. Thus, we focused our
effort on informative markers 3′ to this region, which are located in OPRM1 introns.
First, HWE analyses demonstrated that OPRM1 intronic SNPs affected risk for AD and/or
DD. This approach tests whether genotype frequencies at a locus in a test group reflect an
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equilibrium state, which should occur (in the absence of an effect on phenotype), assuming
no overlapping generations, a large sample size with random mating, no mutation, no
migration and no selection. A genotype distribution that is not in HWE (i.e. is in HWD) in a
case group may suggest an association between this locus and the disease studied (52).
HWD tests have been applied in fine-scale mapping of mutations responsible for diseases
(52–54). Here, we found that the genotypic distributions of four intronic SNPs in Block I
(SNPs 2–5) and three intronic SNPs in Block II (SNPs 10–12) were in HWD in substance
dependent EA subjects (P < 0.05). When the EA case subjects were divided by the substance
of dependence, SNPs 2–5 in Block I and SNPs 11 and 12 in Block II were still in HWD in
EA subjects with AD, and SNPs 4 and 5 in Block I and SNP10 in Block II were still in
HWD in EA subjects with DD. These HWDs suggest that there may be associations between
these markers and diseases.
Although HWD can indicate a valid disease-locus association, two primary alternative
explanations, genotyping error and population admixture, must be considered (55,56). In this
study, genotyping quality was controlled by genotyping DNA samples in duplicate analysis,
which indicated a low genotyping error rate (see ‘Genotyping’ below). In addition, the
influence of some other systematic flaws can be excluded as all selected SNPs were in HWE
in EA control samples. Moreover, Leal (57) reported that if multiple markers that are in LD
are not in HWE, genetic factors rather than genotyping errors would be the expected origin
of the violation of HWE. Therefore, HWD in our cases was unlikely to be due to genotyping
errors. As discussed below, it is also unlikely that population admixture resulted in HWD in
our EA cases.
Second, results from linkage disequilibrium (LD) analyses suggested that SNPs within
intron 1 might confer vulnerability to AD and/or DD. SNP Asn40Asp, located in exon 1, has
been the most commonly studied variant in the OPRM1 gene because of its potential
functional effects. However, the conflicting results regarding this marker prompted us to
assume that another locus influencing the risk to AD and DD might exist elsewhere in
OPRM1 and be in substantial LD with this marker. We used high-density SNP LD mapping
(average distance between SNPs ∼6000 bp) to examine this hypothesis. LD analyses of the
OPRM1 SNP markers in our substance-dependent EA cases showed that SNP Asn40Asp
was in the same haplotype block as six SNPs within intron 1. In particular, pair-wise LD
analyses showed that SNP Asn40Asp was in complete LD (D′ = 1.000) with four of the six
intronic SNP markers in Block I (SNPs 3, 4, 6 and 7) in EA subjects with AD. In EA
subjects with DD, SNP Asn40Asp was in complete LD (D′ = 1.000) with five intronic SNPs
in Block I (SNPs 3–7). Thus, prior positive results with Asn40Asp may be attributable in
part to LD with other functional variants. This could help us explain the observed variability
in association findings with that marker, as LD relationships would be expected to vary
more between populations than do functional effects.
Third, allele-wise and genotype-wise analyses confirmed the association between OPRM1
intronic markers and AD and/or DD. We observed significant differences between
substance-dependent EA cases and controls in allele and/or genotype frequency distributions
of six intronic SNPs in Block I and two intronic SNPs in Block II. As 13 OPRM1 SNP
markers were included in the association analysis, significant adjustment for multiple testing
was necessary. As the 13 OPRM1 SNP markers were located in two separate haplotype
blocks and strong LD between SNPs was observed in each LD block, we used the program
SNPSpD (48) as an alternative to the standard Bonferroni method to correct for multiple
comparisons. This program takes marker LD into consideration and generates an
experiment-wide significance threshold to keep Type I error (or false positive disease
association) less than 0.05. After correction by the latter method (significant threshold P-
value was set at 0.005), association results for SNPs 4 and 5 in Block I and SNPs 11 and 12
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in Block II remained significant. In addition, analysis of four OPRM1 SNP markers (SNPs
4, 5, 11 and 12) in a Russian AD replication sample generally supported the above findings.
The modest significance levels obtained in the Russian population may be attributable to the
comparatively smaller number of Russian control subjects.
Fourth, haplotype-based analyses also supported the association between OPRM1 variants
and substance dependence. As strong LD was observed for the SNPs in the two haplotype
blocks, including all the 13 SNPs in haplotype analysis could substantially dilute the
haplotype association results because of redundancy in the genotype information for some of
the markers. A number of studies have demonstrated that regions of high LD display low
haplotype diversity (58–60). This implies that common haplotypes can be efficiently tagged
using tag SNPs derived from a subset of the common variants. Therefore, to avoid the
inclusion of redundant genotype information for haplotype analysis, using the program
Haploview Tagger (with r2 set at 0.8, as SNPs with shared variance of r2 = 0.8 can be
considered somewhat redundant), we identified three tag SNPs in Block I (SNPs 1, 4 and 5)
and two tag SNPs in Block II (SNPs 11 and 12).
As more than half of the tested markers were not in HWE in the EA cases, the program
PHASE was applied to estimate haplotype frequencies for both EA cases and controls. This
program is based on the Bayesian statistical method and the Partition Ligation algorithm.
Even if HWE is violated, the program PHASE can still be used for reconstructing
haplotypes from the genotype data and for accurately estimating haplotype frequencies (49).
In this study, we found significant associations between the five tag SNP haplotypes and AD
and DD in EA subjects. Moreover, the haplotype results are consistent with those from
allelic association analysis, i.e. haplotype AGTTC, containing major alleles of SNPs 4 and 5
in block I and minor alleles of SNPs 11 and 12 in Block II, was significantly more common
in EA controls than in EA cases, while haplotype AACCT, containing minor allele of SNPs
4 and 5 in Block I and major alleles of SNPs 11 and 12 in Block II, was significantly more
common in EA cases than in EA controls. In addition, haplotype association analysis results
from the Russian samples supported this conclusion.
Fifth, population admixture (in this sample of European ancestry) was excluded as an
explanation for the above findings through the application of a set of AIMs. Based on the
genotype data of the 37 AIMs analyzed using the program STRUCTURE, all self-reported
EA subjects could be assigned to a ‘genetic’ EA population group. This is in agreement with
our own previous observations (45,61) and with the findings by Tang et al. (62) that genetic
clustering for several groups, including EAs, corresponds very closely to self-identified race.
In our EA cases and controls, although no individual had EA ancestry proportion as high as
1.0, the degree of admixture was very low (the average admixture degree being only 1.3%).
In addition, the ancestry proportions of our EA cases were not significantly different from
those of our EA controls when analyzed using the program STRAT. Therefore, there was
minimal potential for Type I errors to result from population stratification.
Finally, logistic regression analyses confirmed the association between OPRM1 gene
variants and AD and/or DD. To reduce the heterogeneity that may confound case-control
studies, ideally, the sex and age of cases and controls should be matched. However, in this
study, the EA cases and controls differed significantly on these variables. Hence, we used
the backward stepwise logistic regression analysis to control for these differences
statistically. This method uses the χ2 statistic to identify variables to be removed from the
model; the covariates remaining in the final regression model contributed most to the
difference between cases and controls. By this method, we found that the minor allele of
SNP5 (rs495491) in Block I was a risk allele for AD and DD via a recessive mode of action,
whereas the minor allele of SNP11 (rs609148) in Block II was a protective allele with
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respect to AD and DD, exerting a dominant effect. These results were in agreement with the
findings by allelic association analyses that the minor alleles of several SNPs (including
SNP5) in Block I were significantly more frequent, whereas the minor alleles of two SNPs
(including SNP11) in Block II were significantly less frequent, in cases than in controls. In
logistic regression analysis, as covariates were included in a single model with allele,
genotype, haplotype or diplotype data, concern over multiple testing is reduced. In the
Russian samples, as both case and control subjects were male and matched on age,
regression analysis was not performed.
Haplotype regression analysis also supported the findings of haplotype association analysis,
i.e. a specific haplotype AGTTC, which harbored major alleles of SNPs 4 and 5 and minor
alleles of SNPs 11 and 12, protected against AD and DD. In addition, we performed the
DTR analysis to verify the finding from individual marker or haplotype analysis. Luo et al.
(52,63) have reported that DTR might be a more powerful approach than haplotype analysis
because it provides more information about the gene and its association with a disease. By
DTR, we found that two diplotypes, harboring the specific haplotype AGTTC, contributed
to the protection against risk for AD and DD. This suggests that interaction of a number of
OPRM1 variants affecting expression (including Asn40Asp) could confer variable liability
to substance dependence. However, we did not observe a greater protective role for the
diplotype homozygous for haplotype AGTTC, despite a frequency of approximately 6%. In
addition, as diplotypes with frequency less than 0.01 were omitted (i.e. 259/1207 = 21.4% of
haplotypes or diplotypes were discarded), we cannot exclude the possibility that certain rare
diplotypes or haplotypes may confer vulnerability to substance dependence.
Although our AD sample was substantially larger than our DD sample, in most cases, we
observed statistically stronger evidence of association for DD than for AD for SNPs from
haplotype block I (Table 1A). This suggests that OPRM1 Block I genetic variation is a more
important predisposing factor for DD than for AD. In contrast, the opposite pattern existed
for SNPs in Block II (Table 1B). We infer from these patterns that there may be two distinct
coding region risk loci mapped to OPRM1, one of which is more important for DD risk
(mapped to the 5′ haplotype block, Block I), and one that is more important for AD risk
(mapped to the 3′ haplotype block, Block II). In addition, the data hint at a possible
difference in mode of action for these distinct loci, with the Block I locus data more
consistent with an allele-wise (recessive) effect and the Block II data more consistent with a
genotype-wise (dominant) effect. One possible explanation for this observation is that the
Block I and Block II variants could act by different functional mechanisms, one of which is
more relevant to DD, and the other, to AD, but it is also possible that this apparent
difference is a chance finding. We predicted that the association would be strongest for
opioiddependent subjects, because of the direct interaction of opioids with the MOR. Further
association analysis was consistent with this prediction (Table 1A and 1B), although the
sample size for OD was small. This apparent difference is easy to understand in the context
of OD and CD pathophysiology; direct opioidergic mechanisms might reasonably be more
important for OD than for CD.
In conclusion, the present study showed that multiple intronic SNPs in OPRM1 may
increase risk for substance dependence in the EA and Russian populations. These data are
consistent with the interpretation that there are at least two bi-allelic risk variants at the
OPRM1 locus, one mapping to the haplotype Block I, and the other, to the haplotype Block
II. In particular, SNPs located in intron 1, which are in close LD with the most frequently
studied SNP Asn40Asp, and SNPs in intron 3, which may be involved in alternative gene
splicing or transcription regulation, are worthy of further investigation. It would be of great
interest to determine if a significant association of substance dependence with OPRM1 gene
variants can be detected in other population groups (e.g. African-Americans). Furthermore,
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it will be important to examine the potential functional effects of these variants, to establish
a mechanism by which they increase or decrease an individual's susceptibility to substance
dependence.
Materials and Methods
Subjects
All subjects provided informed, written consents to participate in this study, which was
approved by the relevant institutional review boards. We recruited 382 EA subjects meeting
the DSM-III-R (American Psychiatric Association, 1987) or DSM-IV (American Psychiatric
Association, 1994) criteria for a lifetime diagnosis of AD and/or DD (cocaine or opioid).
Among them, 318 were affected with AD and 199 were affected with DD, including 171
with CD and 91 with OD. Of the AD–EA subjects, 42.2% (n = 135) had comorbid DD,
whereas more than half of the DD–EA subjects (n = 135 or 67.9%) had comorbid AD. Of
the 382 cases, 287 (75.1%) were male and 95 (24.9%) were female. Subjects' average age
was 40.1 ± 9.6 (mean ± SD) (one subject with age information unknown). Three hundred
and thirty-eight EA control subjects were screened using the Structured Clinical Interview
for DSM-III-R (SCID), the Computerized Diagnostic Interview Schedule for DSM-III-R (C-
DIS-R) or the Schedule for Affective Disorders and Schizophrenia-Lifetime Version
(SADS-L) (64) to exclude major Axis I disorders, including substance dependence,
psychotic disorders (including schizophrenia), major mood disorders and major anxiety
disorders. Among them, 141 (41.7%) were male and 197 (58.3%) were female. The average
age was 27.2 ± 7.9 (mean ± SD) for the 330 EA control subjects whose age was available.
The EA case and control subjects were recruited at either the University of Connecticut
Health Center or the VA Connecticut Healthcare System, West Haven Campus.
In addition, 247 male Russian subjects with AD and 100 male Russian control subjects were
recruited. The method for diagnosis and recruitment has been described earlier by
Lappalainen et al. (51). All AD Russian subjects were recruited at the Leningrad Regional
Center of Addictions (LRCA) affiliated with St Petersburg State Pavlov Medical University.
The standard treatment program in LRCA consists of three phases: inpatient detoxification
(7–10 days), inpatient rehabilitation (3–4 weeks) and follow-up care at an outpatient
psychiatric office or health center. Psychiatric interviews of the participants were conducted
during the inpatient rehabilitation phase. An ICD-10 (International Classification of
Diseases, version 10) diagnosis of AD was established through clinical interviews by a
research psychiatrist. Individuals with primary psychotic disorders were excluded. Ten
percent of the participants fulfilled the diagnostic criteria for lifetime or current drug abuse
or dependence. These participants had been hospitalized for treatment of AD before the
current episode for a median of two times. The participants reported in unstructured
interviews having an average age of onset of drinking of 16 years (SD = 3) and an average
age of onset of heavy drinking (alcohol abuse) of 23 years (SD = 5). Family history of
alcoholism in a first-degree relative was reported by 45% of the participants. The control
group was composed of military personnel of the local subdivision who participated in an
epidemiological study of cardiac disease. The participants were screened using non-
structured clinical interview to exclude the presence of psychiatric and substance use
disorders at the time of recruitment for the study. The average age of Russian cases was 40.0
± 10 (mean ± SD) and for Russian controls, it was 40.0 ± 5 (mean ± SD).
Genotyping
Thirteen SNPs at the OPRM1 locus were selected from the dbSNP database
(http://www.ncbi.nlm.nih.gov/SNP/) of the National Center for Biotechnology Information
(NCBI) (designated by rs#) or from the Applied Biosystems SNP database
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(http://www.appliedbiosystems.com/). These markers cover 80 045 bp of the OPRM1
coding region with an average intermarker spacing of 6157 bp (Fig. 1). SNP1 (or the most
commonly studied SNP Asn40Asp), is in exon 1; SNPs 2–7 are in intron 1; SNP8 is in
intron 2; SNPs 9–12 are in intron 3; SNP13 is in the downstream region of the OPRM1
gene. The heterozygosity of these markers in the NCBI SNP database ranges from 0.101 to
0.499.
SNP Asn40Asp was genotyped by a restriction fragment length polymorphism (RFLP)
genotyping method (27). All other SNPs were genotyped using the TaqMan assay in a 384-
well microplate format. Briefly, 1 ng of DNA was amplified in a final volume of 2 μl
containing 0.05 μl of 20× (or 0.025 μl of 40×) MGB probes and primers, 1 μl of 2× TaqMan
Universal PCR Master Mix, and 0.004 μl of 100× BSA (New England Biolabs Inc., Beverly,
MA). Amplification conditions were 95°C for 10 min, followed by 60 cycles of 92°C for 15
s and 60°C for 1 min. Allelic discrimination was performed using the ABI PRISM® 7900
Sequence Detection System (Applied Biosystems Inc., Foster City, CA, USA). SNPs
genotyped by the Taqman technique were assayed in duplicate and discordant genotypes
were discarded. The genotype discordant (i.e. non-matching) rate was <0.5% for both case
and control samples. For SNPs genotyped by PCR-RFLPs, 8% of samples were re-
genotyped as a quality check, with complete concordance.
For population admixture analysis, 37 AIMs described by Yang et al. (44) and Luo et al.
(45) were genotyped in all the EA case and control subjects. In the Russian sample, we only
genotyped the FY (+/−) SNP, which is the most informative of the AIMs in terms of
differentiating European and African populations. Some of the genotypes for the exon I
variants were included in our earlier reports (27), as were most of the AIM markers (52).
HWE and LD analysis
Deviation from HWE was assessed using the HWSIM program (46). P-values (two-tailed)
were estimated empirically through use of Monte Carlo simulations (10 000 iterations)
based on observed genotype frequency. Significance levels were determined as the
proportion of times the simulated distribution reached or exceeded the observed deviation
from HWE. The program Haploview 3.2 (47) was used to compute pair-wise LD statistics.
Standardized LD coefficients (D′ = D/Dmax, proportion of observed LD out of maximum
possible LD) for all SNP pairs were plotted. Haplotype blocks (segments of strong LD
within which there is little evidence for ancestral recombination events) were defined
according to the criteria of Gabriel et al. (65).
Allelic association study
The program PowerMarker 3.0 (66) was applied in calculating marker allele and genotype
frequencies, as well as testing for association between OPRM1 SNP markers and substance
dependence through the single-locus case control test function in this program package. To
avoid the possibility of false-positive results (i.e. Type I errors), the significance of multi-
locus association studies was corrected for multiple comparisons. The program SNPSpD
(i.e. the SNP spectral decomposition approach) described by Nyholt (48) was used to
generate the experiment-wide significance threshold required to keep Type I error rate
below 5%, taking into account the redundancy of information provided by SNPs which were
in LD.
Tag SNP selection and haplotype analysis
To avoid over-fitting and unbounded haplotype tests in the association analysis, the program
Tagger implemented in Haploview 3.2 (47) was applied to select the tag SNPs that could
efficiently capture common genetic variation in the OPRM1 region. Selection of tag SNPs is
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based on r2, the proportion of total variation in one SNP being explained by another SNP. A
stringent r2 threshold (r2 > 0.8) would allow the selection of a set of tag SNPs to resolve
more than 80% of all existing haplotypes (58).
The possible association of OPRM1 haplotypes (constructed by alleles of the tag SNPs) with
substance dependence was analyzed through the program PHASE 2.1 (49). The advantage
of the algorithm used by PHASE over the Expectation– Maximization (EM) algorithm is its
ability to construct valid haplotypes even when the assumptions of HWE are violated (67).
PHASE not only estimates the probabilities of all likely pairs of haplotypes (i.e. diplotypes)
for each subject from genotype data, but it also provides the overall estimated haplotype
frequency distributions in the whole sample. To produce reliable probability estimates, we
performed 10 000 iterations of each run. In addition, PHASE was used to perform a
permutation test for significant differences in haplotype frequencies between cases and
controls. The number of permutation was set to 20 000.
Population structure analysis
We used the method of Pritchard and Rosenberg (50) to assess the possibility of population
stratification in our EA case and control subjects. The ancestry proportion for each EA
subject was estimated by the program STRUCTURE 2.1 (68) based on the genotype data of
the 37 AIMs. Simulation parameters were set to 100 000 burn-ins followed by 100 000 runs
and K was set to 2. The Pritchard and Rosenberg stratification test statistic was computed
with STRAT software (69) with the output statistic (i.e. the ancestry proportions of EA cases
and controls) generated by the program STRUCTURE as the input file.
Regression analysis
Potential confounding effects due to sex and age differences between cases and controls may
occur. Therefore, a backward stepwise logistic regression method described by Luo et al.
(63) was performed, with the diagnosis as the dependent variable, and the sex and age of
subjects and alleles, genotypes, haplotypes or diplotypes as the independent variables. For
allele data, only the information of the minor allele from each SNP was entered in the
regression model. Minor alleles were coded as 1, 0.5 or 0, respectively, for the minor allele
homozygote, the heterozygote or the major allele homozygote. In the genotype regression
model, we analyzed three modes of inheritance. For recessive inheritance, genotypes were
coded as 1 (the minor allele homozygote) or 0 (heterozygous or homozygous for the major
allele). For dominant inheritance, genotypes were coded as 1 (heterozygous or homozygous
for the minor allele) or 0 (the major allele homozygote). For additive inheritance, genotypes
were coded as 1 (the minor allele homozygote), 0.5 (the heterozygote) or 0 (the major allele
homozygote). In fact, the results generated by the additive mode of inheritance would be the
same as those obtained from allele regression analysis. Haplotype or diplotype probabilities
obtained by the PHASE program were entered in the haplotype or DTR model. Rare
haplotypes or diplotypes with population frequencies less than 0.01 were omitted. In the
regression analyses, only the sex of subjects was used as a categorical variable; all other
variables were numerical. Regression analyses were conducted using the program SPSS 13.0
for Windows (SPSS Inc., Chicago, IL, USA).
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Refer to Web version on PubMed Central for supplementary material.
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Figure 1.
The human μ-opioid receptor gene (OPRM1) structure and 13 SNP variants. SNP1
(rs1799971, 118A/G or Asn40Asp), SNP2 (rs511435, A/G), SNP3 (rs524731, A/C), SNP4
(rs3823010, A/G), SNP5 (rs495491, C/T), SNP6 (rs1381376, A/G), SNP7 (rs3778156, A/
G), SNP8 (rs2075572, C/G), SNP9 (rs548646, C/T), SNP10 (rs9322447, A/G), SNP11
(rs609148, C/T), SNP12 (rs648893, C/T), SNP13 (rs671531, A/G).
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Figure 2.
Linkage disequilibrium (LD) plot of 13 OPRM1 SNPs in EA cases with substance (alcohol
and/or drug) dependence (right) and controls (left). The D′ value corresponding to each SNP
pair is displayed in the square. The numbers in the squares are D′ ×100. Empty squares
meant D′=1 (i.e. complete LD between two SNPs). Squares are colored bright red if the D′
value is high (i.e. LD is strong) and the confidence in the value of D′ is high as well.
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Figure 3.
Association significance (denoted as −log10 P-value) of 13 OPRM1 SNPs in AD, DD, CD
and OD is plotted against the position of SNPs on Chromosome 6. Allele-wise P-values for
AD, DD, CD and OD were designated by triangles, respectively. Genotype-wise P-values
for AD, DD, CD and OD were squares, respectively. (Note that the AD and DD groups
overlap, and the DD group, further, contains the OD and CD groups.)
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